Replies to post #128599 on Biotech Values

[mcbio]

Xu notes Johnson & Johnson (NYSE: JNJ), Boehringer Ingelheim, GaxoSmithKline (NYSE: GSK) and Novartis (NYSE: NVS) are all possible suitors for the acquisition.

William Blair has an Outperform rating and $4 price target on shares of Anadys.

Shares of ANDS are trading up 7.1 percent to just barely over $1. Notably, the stock has not traded over this level since the beginning of August.


pretty good call by this analyst,lol

Well, she did fail to mention Roche as a potential suitor. ; ) Also, JNJ is already partnered with Medivir on a 2nd gen nuke, not to mention TMC435 (2nd gen PI), so I don't know how interested they would be in additional HCV classes. Perhaps BI, GSK, and NVS, among others, would fit the bill as potential partners or acquirers for others in the HCV space, though.

[DewDiligence]

“Xu notes Johnson & Johnson (NYSE: JNJ), Boehringer Ingelheim, GlaxoSmithKline (NYSE: GSK) and Novartis (NYSE: NVS) are all possible suitors for the acquisition…” Pretty good call by this analyst, lol

I agree with the LOL part of your statement. The analyst didn’t mention Roche, the actual acquirer. Moreover, it was dumb of the analyst to include NVS, which has abandoned the HCV arena, as a potential suitor for a company whose only assets are drug candidates for HCV.

The timing of the analyst’s report—as opposed to the content of the prediction—can probably be explained by a leak at ANDS or the investment banker working on the deal.